ArticleBMJ open2024

Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial.

Maohui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.